Literature DB >> 19857586

Myelodysplastic syndromes: from neglect to prominence.

H Joachim Deeg1.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19857586      PMCID： PMC2832713          DOI： 10.1016/j.bbmt.2009.10.020

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  22 in total

1.  Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.

Authors:  B L Scott; B M Sandmaier; B Storer; M B Maris; M L Sorror; D G Maloney; T R Chauncey; R Storb; H J Deeg
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

2.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Authors:  Hagop Kantarjian; Yasuhiro Oki; Guillermo Garcia-Manero; Xuelin Huang; Susan O'Brien; Jorge Cortes; Stefan Faderl; Carlos Bueso-Ramos; Farhad Ravandi; Zeev Estrov; Alessandra Ferrajoli; William Wierda; Jianqin Shan; Jan Davis; Francis Giles; Hussain I Saba; Jean-Pierre J Issa
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

3.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

4.  Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

Authors:  Rodrigo Martino; Simona Iacobelli; Ronald Brand; Thekla Jansen; Anja van Biezen; Jürgen Finke; Andrea Bacigalupo; Dietrich Beelen; Jossy Reiffers; Agnes Devergie; Emilie Alessandrino; Ghulam J Mufti; Renée Barge; Jorge Sierra; Tapani Ruutu; Marc Boogaerts; Michele Falda; Jean-Pierre Jouet; Dieter Niederwieser; Theo de Witte
Journal:  Blood       Date:  2006-04-04       Impact factor: 22.113

5.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

6.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

7.  Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.

Authors:  H Joachim Deeg; Peter Y Z Jiang; Leona A Holmberg; Bart Scott; Effie W Petersdorf; Frederick R Appelbaum
Journal:  Leuk Res       Date:  2004-11       Impact factor: 3.156

Review 8.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

9.  Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

Authors:  Elaine M Sloand; Colin O Wu; Peter Greenberg; Neal Young; John Barrett
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

10.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Authors:  Luca Malcovati; Ulrich Germing; Andrea Kuendgen; Matteo G Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Aristoteles Giagounidis; Barbara Hildebrandt; Paolo Bernasconi; Sabine Knipp; Corinna Strupp; Mario Lazzarino; Carlo Aul; Mario Cazzola
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.